Prevention & lipidsMeta-analysis
Bruton’s tyrosine kinase inhibitors and cardiovascular risk: a meta-analysis
- Systematic review and meta-analysis of randomised trials
- random-effects
- Phase 3 randomized controlled trials (RCTs)
Authors' conclusion
Based on adverse-event reporting from Phase 3 RCTs that does not permit adjustment for competing risks, BTK-I exposure is associated with an increased risk of non-fatal ischaemic MACE.
Study context
- Population
- Adults with B-cell malignancies
- Participants
- 6,799 adults · 17 RCTs
- Comparison
- Bruton's tyrosine kinase inhibitors (BTK-I) vs controls
- Outcome
- Incident non-fatal ischaemic major adverse cardiovascular events (MACE):
- Myocardial ischaemic syndromes
- Ischaemic stroke/TIA
Pooled result
As reported in the abstract
Relative risk
1.66
95% CI 1.09–2.53
P = 0.02
BTK-I vs Controls
RR 1.66 (95% CI 1.09–2.53); P = 0.02
Original publication
Bruton’s tyrosine kinase inhibitors and cardiovascular risk: a meta-analysis. Eur Heart J. Published 8 August 2026. doi:10.1093/eurheartj/ehag613
Summarised from the published abstract; every number is checked against it